Capabilities
A practical, enterprise-grade capability set: discovery support, clinical intelligence, and delivery discipline—built to integrate cleanly.
R&D enablement
Structured research workflows for prioritisation, evidence synthesis, and repeatable decision-making.
Clinical intelligence
Transform clinical and operational data into interpretable outputs for care pathways and planning.
Partnership delivery
Partner-ready execution model across commercialisation, supply pathways, and scalable operations.
R&D enablement
Structured research workflows for prioritisation, evidence synthesis, and repeatable decision-making.
Discovery support
Effective pharmaceutical research and development requires more than scientific insight—it demands structured workflows, rigorous prioritisation, and a repeatable decision-making framework that can withstand scrutiny from partners, regulators, and investors alike. Medyra Health's R&D enablement capability provides exactly this structure, from target identification through to asset prioritisation and evidence synthesis.
Evidence synthesis
Systematic review and synthesis of clinical, pre-clinical, and real-world evidence to support asset prioritisation and development rationale. Our evidence synthesis frameworks are designed to be both scientifically rigorous and practically useful—providing clear, interpretable outputs that inform Go/No-Go decisions at every stage of the development lifecycle.
Triage
Not every opportunity deserves equal resource. Medyra Health's triage capability applies structured multi-criteria assessment to rank and prioritise development opportunities—balancing scientific potential, market opportunity, development risk, and operational resource constraints to ensure that the highest-value programmes receive priority attention and investment.
Target identification
Structured frameworks for biological target selection, incorporating disease relevance, druggability assessment, and competitive landscape analysis.
Feasibility assessment
Technical, regulatory, and commercial feasibility frameworks providing honest early-stage Go/No-Go decision support for development teams.
Portfolio roadmapping
Stage-gated portfolio roadmap design, with clear milestone definitions, resource allocation frameworks, and risk-adjusted valuation tools.
images/cap-rd.jpg
Clinical intelligence
Transform clinical and operational data into interpretable outputs for care pathways and planning.
images/cap-clinical.jpg
Explainable outputs
The healthcare system generates vast quantities of clinical and operational data. The challenge is not data volume—it is the ability to transform that data into interpretable, actionable insight. Medyra Health's clinical intelligence capability is designed for the end user—clinicians, commissioners, and operational managers—ensuring every analytical output is interpretable, actionable, and context-appropriate. We do not produce black-box outputs that require data science expertise to interpret.
Outcomes
Clinical outcome measurement—from patient-reported outcomes through to hard clinical endpoints—is a core component of Medyra Health's clinical intelligence framework. We design outcome measurement strategies that are aligned to regulatory requirements, payer expectations, and the real-world evidence demands of modern healthcare systems, ensuring that outcome data generated is both clinically meaningful and commercially usable.
Operational insight
Workforce planning, capacity modelling, supply chain intelligence, and quality performance monitoring frameworks that enable healthcare operations to run at sustained, measurable performance levels. Medyra Health's operational insight capability translates complex operational data into clear, actionable management information—supporting decision-making from board level through to frontline clinical teams.
Care pathway optimisation
Structured analysis of patient journeys and treatment pathways to identify where intervention can meaningfully improve outcomes and reduce avoidable cost.
Real-world evidence
Post-market evidence generation frameworks that capture real-world product performance and patient experience data to support ongoing regulatory and payer engagement.
Partnership delivery
Partner-ready execution model across commercialisation, supply pathways, and scalable operations.
Co-development
Ideas only create value when they reach patients and healthcare systems. Medyra Health's partnership delivery capability translates scientific and commercial intent into structured, scalable, partner-aligned execution. We are built from the ground up as a partnership-first organisation, and our commercial models, IP structures, and operational frameworks are designed to integrate cleanly with partner organisations—whether global pharma, mid-size biotech, healthcare systems, or technology companies entering the health space.
Scale planning
Operational scale-up planning from proof-of-concept through to commercial-stage production, with quality discipline embedded throughout. Medyra Health's scale planning frameworks are designed to anticipate and address the operational challenges that commonly derail development programmes at the critical late-stage-to-commercial transition—including manufacturing capacity, supply chain resilience, and regulatory readiness.
Governance
Structured governance frameworks and KPI reporting structures that give partners clear, real-time visibility of programme performance, emerging risks, and key decision points. Medyra Health's governance approach is designed to be proportionate—rigorous where it matters, lean where it doesn't—and to support rather than impede the pace of development and delivery.
Commercialisation
Commercial strategy, market access planning, pricing and reimbursement frameworks, and launch readiness support across target markets.
Supply pathways
End-to-end supply chain design, CMO engagement, and logistics framework development aligned to product profile and target market requirements.
Scalable operations
Operational model design that scales efficiently from early commercial launch volumes through to full market penetration, without requiring major structural redesign.
images/cap-partnership.jpg
Discovery support
Building a rigorous foundation for every development programme
Discovery support is the structured process of moving from scientific hypothesis to validated development candidate — selecting the right targets, building the right evidence base, and designing the right experiments to answer the most important questions before significant development investment is committed. Medyra Health's discovery support capability provides the analytical, scientific, and operational scaffolding that makes this process efficient, rigorous, and repeatable.
Target identification
Systematic biological target assessment combining disease relevance, druggability analysis, competitive landscape review, and IP landscape mapping — providing a structured rationale for development candidate selection.
Hit-to-lead progression
Structured criteria and stage-gated decision frameworks for advancing compound or modality candidates from initial hit identification through lead optimisation — with defined Go/No-Go criteria at each stage.
Development candidate nomination
Multi-parameter optimisation frameworks that balance potency, selectivity, pharmacokinetics, manufacturability, and safety signals to nominate the best development candidate from a series — with full scientific and regulatory rationale documentation.
Evidence synthesis
The most complete scientific picture, every time
Evidence synthesis is the systematic identification, appraisal, and integration of all available evidence relevant to a development or clinical decision. At Medyra Health, evidence synthesis is not an afterthought — it is a core discipline that underpins every major programme and asset decision. Our synthesis frameworks draw on PRISMA-compliant systematic review methodology, network meta-analysis, and Bayesian evidence integration to produce the most rigorous and complete evidence picture available.
Systematic review
PRISMA-compliant systematic literature review and meta-analysis services across pre-clinical, translational, and clinical evidence domains — supporting regulatory submissions, scientific advisory board presentations, and partner due diligence.
Indirect treatment comparison
Network meta-analysis and indirect treatment comparison frameworks that enable health economic modelling and comparative effectiveness demonstration in the absence of head-to-head clinical trial data.
Triage
Directing resources to the highest-value opportunities
Not every scientific opportunity deserves equal resource. Pharmaceutical development is resource-intensive, and the opportunity cost of pursuing a sub-optimal programme is both the direct investment consumed and the superior programme not pursued. Medyra Health's triage capability applies structured multi-criteria assessment to prioritise development opportunities — ensuring that the portfolio as a whole is optimally configured for scientific, clinical, and commercial value creation.
Multi-criteria assessment
Structured scoring frameworks that balance scientific novelty, unmet medical need, development risk, time to first milestone, IP position, and commercial potential — producing an evidence-based programme priority ranking.
Portfolio optimisation
Portfolio-level analysis that considers programme interdependencies, shared infrastructure requirements, and strategic fit — optimising resource allocation across a multi-programme portfolio rather than evaluating programmes in isolation.
Go / No-Go criteria
Pre-defined, quantitative stage-gate criteria that remove subjectivity from development progression decisions — ensuring that programmes advance on scientific and clinical merit rather than organisational momentum or sunk-cost bias.
Explainable outputs
Analytical intelligence that clinicians and managers can actually use
The value of any analytical system is determined not by its technical sophistication but by its ability to change decisions for the better. Medyra Health's explainable outputs commitment means that every analytical product we design — whether a clinical decision support algorithm, a supply chain risk dashboard, or an outcomes reporting framework — is built to be understood and trusted by its intended user, without specialist data science interpretation.
Interpretable models
Model design principles that prioritise transparency and interpretability — using SHAP values, feature importance visualisation, and natural language explanation layers to make model outputs understandable to clinical and operational end users.
User-centred design
Co-design processes with clinical and operational end users that ensure analytical outputs are structured, formatted, and delivered in the way that best supports the specific decision context they are designed to inform.
Outcomes
Measuring what matters to patients, payers, and systems
Outcomes measurement — the systematic capture of clinical, patient-reported, and economic outcomes in real-world healthcare settings — is the bedrock of evidence-based medicine, value-based healthcare, and modern pharmaceutical market access strategy. Medyra Health designs outcomes measurement programmes that capture the full value proposition of a therapeutic intervention: clinical efficacy, quality of life improvement, healthcare resource utilisation reduction, and carer burden reduction.
Clinical endpoints
Primary and secondary endpoint selection frameworks aligned to regulatory requirements, payer value frameworks, and clinical practice — ensuring that trial data generated is both approvable and commercially usable.
Patient-reported outcomes
PROM selection, validation, and integration into clinical trials and real-world evidence studies — capturing the patient experience dimension of treatment benefit that clinical endpoints alone cannot measure.
Health economics
Cost-effectiveness modelling, budget impact analysis, and QALY-based value demonstration frameworks aligned to NICE, SMC, AWMSG, and other HTA body requirements across target markets.
Operational insight
Intelligence that runs the organisation better
Operational intelligence is the capacity to translate complex operational data into clear, actionable management information — supporting decisions from board level through to frontline clinical and operational teams. Medyra Health's operational insight capability covers workforce planning, capacity and demand modelling, supply chain performance, quality system analytics, and commercial operations monitoring — providing a comprehensive operational intelligence layer across the full value chain.
Workforce & capacity planning
Demand forecasting, workforce modelling, and capacity optimisation frameworks that enable healthcare systems and pharmaceutical operations to match resources to demand efficiently — reducing both excess cost and service constraint.
Performance dashboards
Real-time KPI monitoring frameworks with exception-based reporting, trend analysis, and early warning indicators — ensuring that management attention is directed to the issues that most require it, rather than diffused across routine reporting noise.
Co-development
Building partnerships that create shared value
Co-development — the structured sharing of development risk, expertise, and resource between two or more organisations — is increasingly the dominant model for pharmaceutical innovation. Medyra Health is built from the ground up as a co-development organisation: our commercial structures, IP frameworks, data governance models, and operational processes are all designed to integrate cleanly with partner organisations and to create genuine shared value rather than zero-sum commercial tension.
Partnership structuring
Co-development agreement design, milestone and royalty structure optimisation, and governance framework development — ensuring that partnership terms are both commercially equitable and operationally workable for all parties.
IP management
Background IP identification, foreground IP allocation, and joint IP governance frameworks that protect each partner's interests while enabling the free flow of scientific information required for effective co-development.
Joint development planning
Integrated development plan design that aligns partner timelines, resource commitments, and decision-making processes into a single, coherent programme plan — with clear accountability and escalation structures.
Scale planning
From proof-of-concept to commercial manufacture
The transition from clinical proof-of-concept to commercial-scale manufacturing is one of the most operationally demanding phases of pharmaceutical development — and one of the most commonly underestimated. Medyra Health's scale planning capability provides the structured operational roadmapping, CMO qualification frameworks, and supply chain design expertise required to execute this transition without programme delay or quality compromise.
Manufacturing scale-up
Process scale-up pathway design from clinical batch size through commercial production — including tech transfer planning, process validation strategy, and CMO qualification frameworks aligned to ICH Q10 pharmaceutical quality system requirements.
Supply chain design
End-to-end supply chain architecture from API sourcing through finished product distribution — with dual-source strategies, inventory buffer planning, and logistics partner qualification to protect supply security at commercial launch and beyond.
Governance
Clarity, accountability, and control at every stage
Effective programme governance — the structures, processes, and behaviours that ensure development programmes are managed with clarity, accountability, and appropriate oversight — is a critical determinant of development success. Medyra Health's governance frameworks are designed to be proportionate: rigorous enough to protect programme integrity and partner confidence, but lean enough to support rather than impede the pace of development and decision-making.
Joint steering committees
JSC design, terms of reference, decision-making protocol, and escalation pathway frameworks that give all co-development partners meaningful governance participation without creating decision bottlenecks.
KPI reporting
Programme KPI framework design and reporting cadence management — providing partners with timely, accurate programme performance data in a format structured for their specific governance and investment oversight requirements.
Risk management
Programme-level risk register design, risk owner assignment, mitigation action tracking, and risk escalation frameworks — ensuring that emerging programme risks are identified, owned, and managed before they become programme-threatening issues.